ROAD TO THE CURE UPDATE JULY 2017

The results are ground-breaking ICB International, Inc., (“ICBII”), has moved closer to halting Parkinson’s disease in patients. The Company has shown that its drug halts Parkinson’s disease in animals, which is dose dependent. For example, animals treated with only two doses, one weekly dose for two weeks, showed up to a 17% decrease in the levels of pathogenic alpha-synuclein in the brain of Parkinson’s mice. However, with six doses, one weekly dose for six weeks, the decrease in the levels of pathogenic alpha-synuclein was 36%. These encouraging animal experiments are a potential prelude to ameliorating pain and sufferings due to neurodegenerative diseases such as Parkinson’s (PD) and Alzheimer’s (AD) diseases, which have afflicted more than 55M worldwide with no cure in sight. The question often asked is: Are the results obtained from animal studies translatable into humans? Regrettably, there are no other animal models available between mice and humans. If the drug fails to show its effectiveness in animals, it cannot be useful in humans. Disease suppression in animals was the first and main, objective of ICBII, which has now been accomplished. The work to determine if ICBII’s drug will perform as well as in humans as it does in mice continues; with the greatest of confidence, the biotech feels that because its drugs easily permeate the blood-brain barrier, there is no reason why they won’t perform as well in humans.

What needs to be done for Human Testing For human testing, ICBI needs to generate more monoclonal drug, which will be accomplished by a process known as “Cloning and Humanization”. Cloning will assist in scaling up the production of ICBII’s drug. Cloning is a known and well-established technique, scientifically very involved and hands-on, labor intensive.  ICBI needs to hire a group of scientists to start the cloning experiments which is estimated to be between 9 and 15 months to bring to fruition. Additional time is needed for large-scale production, purification, and validation of the cloned drug by replicating some of the previous experiments such as imaging data before. All this in preparation for submitting the IND application with the USFDA for studying the drug in humans.

SUMMARY Patients can expect good times approaching them because ICBII’s technology has the potential to suppress and halt Parkinson’s disease. HOW CAN YOU HELP? The joy of being a part of this historical event can be had by helping ICBII find the funds to bring these trials to fruition through your personal, including your IRA, investment, and/or by finding others with the financial ability and humanitarian mindset to accomplish the, until now, impossible. Please contact Jo Rosen at Parkinson’s Resource Organization at 760-773-5628 or Jo Rosen@Parkinsonsresource.org. Contact ICBII directly through their website ICBII.com, or by phone, 858-455-9880. IMAGINE, the world without Parkinson’s or Alzheimer’s disease. Just Imagine.